Glycoprotein IIB/IIIA inhibitor: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Background== *By competing with fibrinogen and von Willebrand factor (vWF) for GP IIb/IIIa binding, GP IIb/IIIa antagonists interfere with platelet cross-linking and platele...") |
ClaireLewis (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
*Mostly indicated for patients undergoing PCI for [[ACS]] | *Mostly indicated for patients undergoing PCI for [[ACS]] | ||
==Glycoprotein IIB/IIIA inhibitors | ==Glycoprotein IIB/IIIA inhibitors== | ||
*[[Abciximab]] (ReoPro) | |||
*[[Eptifibatide]] (Integrilin) | |||
*[[Tirofiban]] (Aggrastat) | |||
[[category:Pharmacology]] | |||
Latest revision as of 01:22, 22 October 2020
Background
- By competing with fibrinogen and von Willebrand factor (vWF) for GP IIb/IIIa binding, GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation
- Mostly indicated for patients undergoing PCI for ACS
Glycoprotein IIB/IIIA inhibitors
- Abciximab (ReoPro)
- Eptifibatide (Integrilin)
- Tirofiban (Aggrastat)